HC Wainwright Issues Positive Estimate for OptiNose Earnings

OptiNose, Inc. (NASDAQ:OPTN) – HC Wainwright raised their FY2024 earnings per share estimates for shares of OptiNose in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.18) per share for the year, up from their previous estimate of ($0.22). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OptiNose’s FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.35 EPS.

Separately, Piper Sandler dropped their price target on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday.

OptiNose Stock Down 4.4 %

OPTN stock opened at $0.44 on Friday. OptiNose has a twelve month low of $0.41 and a twelve month high of $2.10. The stock has a market capitalization of $65.61 million, a price-to-earnings ratio of -1.55 and a beta of -0.07. The firm’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $0.95.

Hedge Funds Weigh In On OptiNose

A number of large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC lifted its position in shares of OptiNose by 442.3% during the second quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock worth $14,425,000 after purchasing an additional 10,944,444 shares during the last quarter. Great Point Partners LLC increased its stake in OptiNose by 56.2% in the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock worth $14,276,000 after buying an additional 4,940,779 shares during the period. Stonepine Capital Management LLC lifted its holdings in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock valued at $3,811,000 after buying an additional 3,338,580 shares in the last quarter. Rosalind Advisors Inc. boosted its position in OptiNose by 66.2% in the 2nd quarter. Rosalind Advisors Inc. now owns 7,547,148 shares of the company’s stock valued at $7,849,000 after buying an additional 3,005,659 shares during the period. Finally, FMR LLC grew its stake in OptiNose by 3.2% in the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock worth $11,083,000 after acquiring an additional 518,610 shares in the last quarter. Hedge funds and other institutional investors own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.